- Home
- OMCL vs AKRO Comparison
OMCL vs AKRO Comparison
Compare OMCL & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMCL
- AKRO
- Stock Information
- Founded
- OMCL 1992
- AKRO 2017
- Country
- OMCL United States
- AKRO United States
- Employees
- OMCL N/A
- AKRO N/A
- Industry
- OMCL Computer Manufacturing
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- OMCL Technology
- AKRO Health Care
- Exchange
- OMCL Nasdaq
- AKRO Nasdaq
- Market Cap
- OMCL 1.3B
- AKRO 3.9B
- IPO Year
- OMCL 2001
- AKRO 2019
- Fundamental
- Price
- OMCL $29.84
- AKRO $51.77
- Analyst Decision
- OMCL Buy
- AKRO Strong Buy
- Analyst Count
- OMCL 6
- AKRO 6
- Target Price
- OMCL $44.83
- AKRO $82.50
- AVG Volume (30 Days)
- OMCL 472.7K
- AKRO 1.7M
- Earning Date
- OMCL 07-31-2025
- AKRO 08-08-2025
- Dividend Yield
- OMCL N/A
- AKRO N/A
- EPS Growth
- OMCL N/A
- AKRO N/A
- EPS
- OMCL 0.45
- AKRO N/A
- Revenue
- OMCL $1,135,755,000.00
- AKRO N/A
- Revenue This Year
- OMCL $3.84
- AKRO N/A
- Revenue Next Year
- OMCL $4.07
- AKRO N/A
- P/E Ratio
- OMCL $65.79
- AKRO N/A
- Revenue Growth
- OMCL 3.00
- AKRO N/A
- 52 Week Low
- OMCL $22.66
- AKRO $21.02
- 52 Week High
- OMCL $55.75
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- OMCL 53.19
- AKRO 48.51
- Support Level
- OMCL $28.80
- AKRO $51.08
- Resistance Level
- OMCL $30.57
- AKRO $57.35
- Average True Range (ATR)
- OMCL 0.78
- AKRO 2.17
- MACD
- OMCL 0.10
- AKRO -0.82
- Stochastic Oscillator
- OMCL 74.56
- AKRO 8.17
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.